Accueil   Diary - News   All news Voxcan at the forefront of COVID-19 research

Voxcan at the forefront of COVID-19 research



Since the emergence of COVID-19, Voxcan has striven to dedicate its 400 sqm² of state-of-the-art facilities, including BSL3,  and 14 years of experience in preclinical studies to helping pharmaceutical companies fight against the pandemic. As a result, Voxcan has successfully implemented two SARS-CoV-2 preclinical models for testing the efficacy of vaccine and antiviral candidates, with 8 COVID-19 programs already completed for Pharma and Biotech companies since the first quarter of 2021.



SARS-CoV-2 preclinical models available at Voxcan



Voxcan has fully characterised both K18-hACE2 mouse and Syrian golden hamster models of SARS-CoV-2 infection. Infection is carried out intranasally, with the primary strain or emerging UK and South-African variants. Both mouse and hamster models exhibit viral replication in the upper and lower respiratory tract, as well as different degrees of symptoms due to the host response (weight loss and lung histopathological changes).



Customizable services for evaluating antiviral and vaccine therapies efficacy against SARS-CoV-2



Models implemented at Voxcan are fully customizable and well suited to study the efficacy of vaccine and antiviral therapies against SARS-CoV-2. Drug candidates can be administered therapeutically or prophylactically, with a wide range of routes available (locally via intranasal instillation or intratracheal aerosolization, systemically via intraperitoneal, intramuscular route or oral gavage, etc.). Viral load can be monitored in upper and lower airways, by RT-qPCR or via quantifying the actual titer of infective viral particles by PFU counting. To follow the host response, weight loss, clinical signs and organ histopathology can be assessed at specific timepoints, as well as cytokine levels using RT-qPCR.



Thanks to its experience in providing preclinical models for emerging infectious diseases, Voxcan is constantly working to provide the most relevant models. As such, experts at Voxcan are currently developing co-infection models with SARS-CoV-2 and KAPE bacteria, to model secondary pneumoniae in hospitalized patients.



More information on SARS-CoV-2 services at Voxcan is available at For any query and discussion about models and study designs, please feel free to email